RxDoctor Payments Data

Nanyoung Park

Adult Health · Duluth, GANPI 1043633084

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.9% of the total across 398 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 7.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,410, 4.2 times the $572 reported in 2021. Among adult health clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,882in general payments, 2019–2025

Across 398 payments — averaging $22.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$700
  • Merck$655
  • Johnson & Johnson$652
  • Novartis$554
  • Bristol Myers Squibb$494
  • Seagen Inc.$424
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$8,78799%
  • Education$951%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)32$700
Merck23$655
Johnson & Johnson(2 entities)31$652
Novartis26$554
Bristol Myers Squibb23$494
Seagen Inc.22$424
Daiichi Sankyo Inc.17$423
Pfizer25$415
Genentech USA, Inc.14$296
Eisai Inc.10$244
GSK10$243
AbbVie10$243
Astellas Pharma US Inc8$206
Amgen10$179
Incyte Corporation9$172
Beone Medicines USA, Inc.6$149
Stemline Therapeutics Inc.6$141
E.r. Squibb & Sons, L.L.C.7$138
Deciphera Pharmaceuticals Inc.7$136
Ipsen Biopharmaceuticals, Inc5$136
Takeda Pharmaceuticals U.S.A., Inc.4$130
Beigene USA, Inc.6$127
Coherus Oncology, Inc.6$123
Karyopharm Therapeutics Inc.5$109
Novo Nordisk1$107
Pharmacyclics LLC, An Abbvie Company4$105
ADC Therapeutics America, Inc.5$99
Bayer4$91
Exelixis Inc.3$78
Sobi, Inc3$77
Dendreon Pharmaceuticals LLC3$77
Foundation Medicine, Inc.3$69
Puma Biotechnology, Inc.3$67
Sanofi3$66
Regeneron Healthcare Solutions, Inc.3$63
Gilead3$60
AVEO Pharmaceuticals, Inc.2$57
Tempus AI, Inc2$57
Jazz Pharmaceuticals Inc.2$56
Servier Pharmaceuticals LLC3$54
Mirati Therapeutics, Inc.2$52
Array Biopharma Inc3$46
Adaptive Biotechnologies Corporation2$43
Caris MPI, Inc.2$41
Lilly USA, LLC2$38
Tersera Therapeutics LLC2$38
Blueprint Medicines Corporation1$37
Sun Pharmaceutical Industries Inc.1$33
Boehringer Ingelheim1$31
Inari Medical, Inc.1$30
Alnylam Pharmaceuticals Inc.1$27
G1 Therapeutics, Inc.1$22
Myovant Sciences Inc.1$22
Ferring Pharmaceuticals Inc.1$20
Immunogen, Inc.1$19
Exact Sciences1$18
Dova Pharmaceuticals1$17
Morphosys, US Inc.1$16
Myriad Genetic Laboratories, Inc.1$16
Kowa Pharmaceuticals America, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,882 in reported general payments places this provider in the 95th percentile of 577 adult health providers in Georgia.

See all adult health providers in Georgia

Medicare billing

Part B allowed, 2024
$19,410
Medicare patients
81
Services billed
290

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
DopteletAvatrombopag Maleate13$326,365
JakafiRuxolitinib Phosphate11$204,602
Imatinib Mesylate14$20,382
EliquisApixaban17$9,278
Tenofovir Disoproxil Fumarate13$7,358
Exemestane11$1,858
Anastrozole70$860
ValacyclovirValacyclovir Hcl20$498
Dexamethasone31$304
Ondansetron OdtOndansetron20$156
Hydroxyurea14$137
Gabapentin12$117
Tamoxifen Citrate11$113
Prednisone20$30
Tramadol Hcl11$27

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dova PharmaceuticalsDoptelet$17$326,36513 claims
Incyte CorporationJakafi$172$204,60211 claims
PfizerEliquis$415$9,27817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 577 adult health providers in Georgia.

Other adult health in Duluth

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →